Pharmacokinetics, Efficacy and Safety of the 304 Injection
Status:
Unknown status
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304
injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin
lymphoma who had previously achieved CR/CRu status but had not deteriorated or relapsed.
While to assess the safety and efficacy of the experimental drug 304 injection compared with
rituximab injection.